Several first-line combinations of platinum-based chemotherapy (ChT) plus an immune-checkpoint inhibitor successfully confirmed improved overall survival compared with ChT alone for mNSCLC patients, regardless of tumor PD-L1 status. This evidence concerns the gene CD274 and neoplasm.